目的 探讨维肝福泰片联合恩替卡韦分散片治疗活动性代偿期乙型肝炎肝硬化的临床疗效。方法 选择2015年1月-2016年7月成都市双流区第一人民医院收治的活动性代偿期乙型肝炎肝硬化患者122例作为研究对象，采用随机数字表法将所有患者分为对照组和治疗组，每组各61例。对照组口服恩替卡韦分散片，1片/次，1次/d。治疗组在对照组基础上口服维肝福泰片，3片/次，3次/d。观察两组的临床疗效，比较两组的乙型肝炎病毒的脱氧核糖核酸（HBV-DNA）水平、血清肝功能指标、肝脾影像学指标和肝纤维化指标。结果 治疗后，对照组和治疗组的总有效率分别为72.1%、93.4%，两组比较差异有统计学意义（P<0.05）。治疗后，两组HBV-DNA水平显著下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组HBV-DNA水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗24、48周后，两组血清中丙氨酸氨基转移酶（ALT）、总胆红素（TBIL）、天门冬氨酸氨基转移酶（AST）水平均明显降低，白蛋白（ALB）均明显升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组这些肝功能指标的同期改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗24、48周后，两组门静脉内径（Dpv）、脾厚度、脾静脉内径（Dsv）均明显降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组这些肝脾影像学指标同期明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗24、48周后，两组透明质酸（HA）、Ⅲ型前胶原（PC-Ⅲ）、层粘蛋白（LN）、Ⅳ型胶原（Ⅳ-C）水平均明显降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组这些肝纤维化指标明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 维肝福泰片联合恩替卡韦分散片治疗活动性代偿期乙型肝炎肝硬化具有较好的临床疗效，可有效抑制HBV的复制，改善肝功能和肝纤维化，具有一定的临床推广应用价值。

Objective To study the clinical effects of Weigan Futai Tablets combined with Entecavir Dispersible Tablets in treatment of hepatitis B cirrhosis in active compensatory period. Methods Patients (122 cases) with hepatitis B cirrhosis in active compensatory period in the First People's Hospital of Shuangliu District from January 2015 to July 2016 were randomly divided into control and treatment groups, and each group had 61 cases. Patients in the control group were po administered with Entecavir Dispersible Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Weigan Futai Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 48 weeks. After treatment, the clinical efficacies were evaluated, and HBV-DNA levels, liver function indexes, liver and spleen imaging indexes, and liver fibrosis indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 72.1% and 93.4%, respectively, and there was difference between two groups (P < 0.05). After treatment, the HBV-DNA levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the HBV-DNA levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment for 24 and 48 weeks, the levels of ALT, TBIL, and AST in two groups were significantly decreased, but the levels of ALB in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the liver function indexes in the treatment group were significantly better than those in the control group at the same time, with significant difference between two groups (P < 0.05). After treatment for 24 and 48 weeks, Dpv, splenic thickness, and Dsv in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the liver and spleen imaging indexes in the treatment group were significantly lower than those in the control group at the same time, with significant difference between two groups (P < 0.05). After treatment for 24 and 48 weeks, the levels of HA, PC-Ⅲ, LN, and Ⅳ-C in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the liver fibrosis indexes in the treatment group were significantly lower than those in the control group at the same time, with significant difference between two groups (P < 0.05). Conclusion Weigan Futai Tablets combined with Entecavir Dispersible Tablets has clinical curative effect in treatment of hepatitis B cirrhosis in active compensatory period, can effectively inhibit HBV replication, improve liver function and liver fibrosis, which has a certain clinical application value.